151 completed, 36 recruiting, 34 unknown, 14 terminated. 75 Phase 3, 48 Not applicable, 45 Phase 2, 19 Phase 1, 12 Phase 4.
Follow Hyperlipoproteinemia Type II: new trials by email Literature Review of Hyperlipoproteinemia Type II trials Research Report on Hyperlipoproteinemia Type II
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP Cascade testing, Standard of Care - Familial Hypercholesterolemia | Not applicable | Not yet recruiting | Mayo Clinic | 480 | 2026-10-20 | 2026-09-18 |
| An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia Hypercholesterolaemia, Familial Hypercholesterolaemia | Not yet recruiting | Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) | 2500 | 2026-10-01 | 2026-08-21 | |
| Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia Zodasiran - Homozygous Familial Hypercholesterolemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 10 | 2026-10-01 | 2026-10-06 |
| A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia SYH2070, Placebo - Mixed Hyperlipidemia | Phase 2 | Recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 240 | 2026-07-15 | 2026-07-22 |
| Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography | Recruiting | Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) | 52 | 2026-04-30 | 2026-08-21 | |
| A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease | Recruiting | Novartis Pharmaceuticals | 5995 | 2026-04-02 | 2026-07-15 | |
| IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia IBI306, placebo - Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 198 | 2026-04-01 | 2026-08-14 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy SYH2053/placebo injection - Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Not yet recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 900 | 2026-03-31 | 2026-02-19 |
| QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia QLC7401, Placebo - Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 510 | 2026-03-05 | 2026-03-02 |
| QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C) QLC7401, Placebo - Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 780 | 2026-03-01 | 2026-03-04 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia SYH2053 injection, SYH2053 injection placebo - Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 760 | 2026-02-28 | 2026-04-07 |
| The ORIGIN-FH Study Screening for FH - Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH) | Not applicable | Recruiting | University of Wisconsin, Madison | 70 | 2026-02-14 | 2026-10-13 |
| A Dose-exploration Study of EDP167 in HoFH EDP167 - Homozygous Familial Hypercholesterolemia (HoFH) | Phase 2 | Recruiting | Eddingpharm (Zhuhai) Co., Ltd. | 20 | 2026-02-06 | 2026-05-20 |
| Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol Rosuvastatin + Ezetimibe, Bempedoic Acid + Ezetimibe, Rosuvastatin + Ezetimibe + Bempedoic Acid - Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol | Phase 4 | Completed | Bahria University | 126 | 2026-01-01 | 2026-10-20 |
| Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia ARO-DIMERPA, Placebo - Hyperlipidemia; Mixed | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 78 | 2025-12-22 | 2026-10-13 |
| Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) Coronary CT scan with CAC score measurement - Familial Hypercholesterolemias, Atherosclerotic Cardiovascular Disease (ASCVD) | Not applicable | Recruiting | Nantes University Hospital | 600 | 2025-09-25 | 2026-03-19 |
| Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia SHR-1918 - Homozygous Familial Hypercholesterolemia | Phase 2 | Not yet recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 55 | 2025-08-01 | 2025-08-21 |
| A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) zodasiran Injection, Placebo - Homozygous Familial Hypercholesterolemia | Phase 3 | Active not recruiting | Arrowhead Pharmaceuticals | 70 | 2025-06-17 | 2026-08-12 |
| National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry whole genome sequencing - Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated | Recruiting | Hospital do Coracao | 1211 | 2025-04-30 | 2026-05-08 | |
| A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan Bempedoic acid 180 mg tablet - Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 4 | Completed | Daiichi Sankyo | 180 | 2025-04-01 | 2025-12-08 |
Showing 20 of 269. Sign in to see all of them.
Homozygous Familial Hypercholesterolemia (67) · Hypercholesterolemia (62) · Atherosclerosis (25) · Hyperlipidemias (24) · Cardiovascular Diseases (23) · Dyslipidemias (21) · Metabolic Diseases (12) · Genetic Diseases, Inborn (11) · Hypertriglyceridemia (11) · Lipid Metabolism Disorders (11) · Lipid Metabolism, Inborn Errors (7) · Coronary Artery Disease (6) · Hyperlipoproteinemias (6) · Metabolism, Inborn Errors (5)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (268) · Nutritional and Metabolic Diseases (268) · Metabolism, Inborn Errors (264) · Hyperlipoproteinemias (263) · Lipid Metabolism, Inborn Errors (262) · Genetic Diseases, Inborn (258) · Lipid Metabolism Disorders (258) · Metabolic Diseases (257) · Dyslipidemias (248) · Hyperlipidemias (245) · Vascular Diseases (42) · Arterial Occlusive Diseases (31) · Cardiovascular Diseases (31) · Arteriosclerosis (30)
Ezetimibe (15) · Atorvastatin (13) · evolocumab (12) · ALN-PCS (11) · Rosuvastatin Calcium (9) · BMS201038 (8) · Niacin (7) · MK-0524 (6) · Saline Solution (6) · Simvastatin (6) · mipomersen (6) · evinacumab (5) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (4) · Colesevelam Hydrochloride (4) · Fenofibrate (4)
Merck Sharp & Dohme LLC (15) · Novartis Pharmaceuticals (11) · Organon and Co (11) · Aegerion Pharmaceuticals, Inc. (6) · Amgen (6) · Kastle Therapeutics, LLC (6) · Laval University (6) · University of Pennsylvania (6) · Arrowhead Pharmaceuticals (5) · AstraZeneca (5) · Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) (5) · Regeneron Pharmaceuticals (5) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (4) · Pfizer (4) · Verve Therapeutics, Inc. (4)
United States (87) · Canada (57) · Netherlands (44) · China (27) · South Africa (27) · United Kingdom (27) · France (26) · Italy (25) · Spain (21) · Germany (19) · Norway (18) · Australia (17) · Czechia (17) · Turkey (Türkiye) (17) · Taiwan (15)
Marina Cuchel, MD, PhD (5) · Aline Marcadenti, PhD (2) · Erlon O Abreu-Silva, MSc (2) · Fernando Civeira, MD, PhD (2) · Jean-Claude Tardif, MD (2) · Jean-Philippe Drouin-Chartier (2) · Marc Ditmarsch (2) · Mark Sumeray, MD (2)
PMID 33990512, PMID 27578134, PMID 34617591, PMID 36520008, PMID 17407645, PMID 19029469, PMID 21401833, PMID 21613319, PMID 22087637, PMID 22500948, PMID 24014831, PMID 25614280, PMID 32609313, PMID 35916348, PMID 40587053, PMID 11914243, PMID 12034651, PMID 15247520, PMID 17215532, PMID 17387131, PMID 17520105, PMID 17630038, PMID 18376000, PMID 18650989, PMID 18996523, PMID 19081418, PMID 19195513, PMID 19576324, PMID 20110022, PMID 20223367, PMID 20227758, PMID 20228610, PMID 20645885, PMID 20707601, PMID 20816118, PMID 20934572, PMID 22305632, PMID 22592524, PMID 22658147, PMID 23060426, PMID 23323877, PMID 23684512, PMID 24094767, PMID 24192652, PMID 24206527, PMID 24366918, PMID 24854458, PMID 24855368, PMID 24899155, PMID 25282520
2017 (5), 2005 (3), 2015 (3), 2016 (3), 2008 (1), 2018 (1), 2019 (1), 2025 (1), P01HL059407 (1), P01HL116263 (1), R01HG009671 (1), R01HL031497 (1), R61HL161775 (1), U01HG006379 (1)